

PARERA-PASCUAL MM, PÉREZ DE AMEZAGA-TOMÁS L, CALDERÓN HERNANZ B, BRADY-GARCIA A, CRESPI-CIFRE MA, CABALLERO-SÁNCHEZ M, VILANOVA-BOLTÓ M
HOSPITAL UNIVERSITARI SON LLÀTZER, HOSPITAL PHARMACY, PALMA DE MALLORCA, SPAIN.

4CPS-156

Contact data: nenaparera@gmail.com

BACKGROUND AND IMPORTANCE

EU legislation does not regulate how drugs are ultimately used in medical practice. In response, the **Royal Decree 86/2015 regulates the Pharmacy and Therapeutics Committee of the Balearic Islands**, an advisory panel of experts composed by **pharmacists and physicians**, which elaborate technical reports to **allow or deny drugs prescribed in special situations**: off-label drugs (OLDs), compassionate drugs (CDs) and drugs not included in the hospital's pharmacotherapeutic guide (HPG).

AIM AND OBJECTIVES

To analyse the clinical response achieved by the treatments approved by P&T-Committee and their associated costs.

MATERIALS AND METHODS



Prospective study of the drugs requested to the P&T-Committee between January/20-December/21.



The variables were **type of treatment** (OLD, CD or not included in the HPG), **level of evidence**, **clinical response**, **adverse effects** and **costs**.



Clinical response was defined as **success** or **failure** based on the therapeutic objective established by the physician at the time of the request,




The cost was calculated **based on the duration of the treatment** until the **objective was achieved** or until **treatment was discontinued**.


RESULTS




182 approved requests



Level of evidence



Type of treatment



The overall estimated cost was **3.672.751,93€**



The medical services with the greatest impact were

Oncology (35.307,22€/treatment)

Haematology (20.686,16€/treatment)

CONCLUSION AND RELEVANCE

The percentage of treatments analysed that achieved their therapeutic goal was very similar to those that didn't, probably because of the **high level of heterogeneity of the treatments analysed**. However, we can't ignore the **high economic impact of these drugs** and **we need to define therapy follow-up plans**.